[{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Wacker Chemie AG \/ Wacker","highestDevelopmentStatusID":"10","companyTruncated":"Wacker Chemie AG \/ Wacker"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Caeregen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"CTR-107","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Wacker Chemie AG \/ Caeregen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Wacker Chemie AG \/ Caeregen Therapeutics"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Pantherna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"PAN004","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Wacker Chemie AG \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Wacker Chemie AG \/ Pantherna Therapeutics"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"MinervaX ApS","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"GBS-NN\/NN2","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Wacker Chemie AG \/ MinervaX ApS","highestDevelopmentStatusID":"14","companyTruncated":"Wacker Chemie AG \/ MinervaX ApS"}]

Find Clinical Drug Pipeline Developments & Deals by Wacker Chemie AG

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The collaboration aims to manufacture MinervaX's active protein ingredients of its GBS vaccine, GBS NN, a novel, prophylactic vaccine against Group B Streptococcus.

                          Brand Name : GBS-NN/NN2

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 17, 2024

                          Lead Product(s) : GBS-NN/NN2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : MinervaX ApS

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.

                          Brand Name : PAN004

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 07, 2024

                          Lead Product(s) : PAN004

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Pantherna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The collaboration aims for the development and production of Noregen (CTR-107), a novel regenerative therapeutic, for treating retinal-related vision loss. CTR-107 is the first program to obtain FDA Rare Pediatric Disease Designation for Familial Exudati...

                          Brand Name : Noregen

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 28, 2023

                          Lead Product(s) : CTR-107

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Caeregen Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021.

                          Brand Name : CVnCoV

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          November 23, 2020

                          Lead Product(s) : CVnCoV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : CureVac

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank